NIGHTHAWK BIOSCIENCES INC (NHWK) Fundamental Analysis & Valuation
NYSEARCA:NHWK • US42237K4094
Current stock price
0.4135 USD
+0.03 (+8.96%)
At close:
0.4299 USD
+0.02 (+3.97%)
After Hours:
This NHWK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NHWK Profitability Analysis
1.1 Basic Checks
- NHWK had negative earnings in the past year.
- NHWK had a negative operating cash flow in the past year.
1.2 Ratios
- NHWK's Return On Assets of -74.32% is on the low side compared to the rest of the industry. NHWK is outperformed by 71.89% of its industry peers.
- The Return On Equity of NHWK (-143.11%) is worse than 65.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROIC | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NHWK has a Gross Margin of 28.70%. This is in the better half of the industry: NHWK outperforms 76.43% of its industry peers.
- The Profit Margin and Operating Margin are not available for NHWK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. NHWK Health Analysis
2.1 Basic Checks
- NHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for NHWK has been increased compared to 1 year ago.
- Compared to 1 year ago, NHWK has a worse debt to assets ratio.
2.2 Solvency
- NHWK has an Altman-Z score of -6.72. This is a bad value and indicates that NHWK is not financially healthy and even has some risk of bankruptcy.
- NHWK's Altman-Z score of -6.72 is on the low side compared to the rest of the industry. NHWK is outperformed by 72.22% of its industry peers.
- NHWK has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
- NHWK has a worse Debt to Equity ratio (0.25) than 71.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.72 |
ROIC/WACCN/A
WACC10.89%
2.3 Liquidity
- NHWK has a Current Ratio of 0.99. This is a bad value and indicates that NHWK is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.99, NHWK is not doing good in the industry: 90.40% of the companies in the same industry are doing better.
- NHWK has a Quick Ratio of 0.99. This is a bad value and indicates that NHWK is not financially healthy enough and could expect problems in meeting its short term obligations.
- NHWK has a Quick ratio of 0.99. This is amonst the worse of the industry: NHWK underperforms 89.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. NHWK Growth Analysis
3.1 Past
- The earnings per share for NHWK have decreased strongly by -21.47% in the last year.
- The Revenue has grown by 147.78% in the past year. This is a very strong growth!
- The Revenue has been growing by 33.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
3.2 Future
- The Earnings Per Share is expected to grow by 18.45% on average over the next years. This is quite good.
- The Revenue is expected to grow by 71.98% on average over the next years. This is a very strong growth
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. NHWK Valuation Analysis
4.1 Price/Earnings Ratio
- NHWK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NHWK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NHWK's earnings are expected to grow with 18.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y18.45%
5. NHWK Dividend Analysis
5.1 Amount
- NHWK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NHWK Fundamentals: All Metrics, Ratios and Statistics
0.4135
+0.03 (+8.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2023-11-20/amc
Earnings (Next)03-29 2024-03-29/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.34M
Revenue(TTM)2.23M
Net Income(TTM)-51.95M
Analysts43.33
Price Target10.2 (2366.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.76%
Min EPS beat(2)-40.06%
Max EPS beat(2)-15.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-55.88%
Max Revenue beat(2)26.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.98
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% | ||
| FCFM | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 43.83% | ||
| Cap/Sales | 121.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | -6.72 |
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)351.08%
Cap/Depr(5y)283.29%
Cap/Sales(3y)138.98%
Cap/Sales(5y)87.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
EBIT growth 1Y-45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.4%
OCF growth 3YN/A
OCF growth 5YN/A
NIGHTHAWK BIOSCIENCES INC / NHWK Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to NHWK.
What is the valuation status for NHWK stock?
ChartMill assigns a valuation rating of 0 / 10 to NIGHTHAWK BIOSCIENCES INC (NHWK). This can be considered as Overvalued.
How profitable is NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
NIGHTHAWK BIOSCIENCES INC (NHWK) has a profitability rating of 1 / 10.
What is the financial health of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
The financial health rating of NIGHTHAWK BIOSCIENCES INC (NHWK) is 0 / 10.